TerminatedNCT00374543
Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolarity
Medication studyAges 18–75United States
Understand this study
Who could participate?
Listed age limits: 18 years to 75 years.
- Listed locations
- BostonSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateFebruary 2006
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 3
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT00374543
- Official title
Show the full official title
Ziprasidone for the Treatment of Generalized Anxiety Comorbidity in Patients With Bipolar Disorder
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Boston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Ziprasidone and Placebo.
Who can participate?
Listed age limits: 18 years to 75 years.
Is this study still recruiting?
The registry lists this study as terminated.
